Evidence map›Paper›PMID 29775646›Full record

ArticleExperimental hematology2018

The RNA binding protein Ars2 supports hematopoiesis at multiple levels.

Seerat Elahi, Shawn M Egan, G Aaron Holling, Rachel L Kandefer, Michael J Nemeth, Scott H Olejniczak

Abstract read
In one paragraph

Article in Experimental hematology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Seerat ElahiDepartment of Pathology and Anatomical Sciences, State University of New York at Buffalo, Buffalo, NY, USA; Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY, USA.
Shawn M EganDepartment of Immunology, Roswell Park Cancer Institute, Buffalo, NY, USA.
G Aaron HollingDepartment of Immunology, Roswell Park Cancer Institute, Buffalo, NY, USA.
Rachel L KandeferDepartment of Immunology, Roswell Park Cancer Institute, Buffalo, NY, USA.
Michael J NemethDepartment of Immunology, Roswell Park Cancer Institute, Buffalo, NY, USA; Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA.
Scott H OlejniczakDepartment of Pathology and Anatomical Sciences, State University of New York at Buffalo, Buffalo, NY, USA; Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY, USA. Electronic address: scott.olejniczak@roswellpark.org.
Roswell Park Comprehensive Cancer Center · US

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MARK G FRATTINI · 1985 to 2026
$116.6M
MULTIDISCIPLINARY APPROACHES TUMOR IMMUNOLOGYT32CA085183 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI Scott I. Abrams · 2001 to 2026
$3.1M
Reciprocal regulation of microRNAs and cancer-associated signaling pathwaysR00CA175189 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI OLEJNICZAK, SCOTT HENRY · 2015 to 2017
$674k
NCI NIH HHS P30 CA016056NCI NIH HHS R00 CA175189NCI NIH HHS T32 CA085183
6 · The paper itself

Abstract

Recent biochemical characterization of arsenic resistance protein 2 (Ars2) has established it as central in determining the fate of nascent ribonucleic acid (RNA) polymerase II (RNAPII) transcripts. Through interactions with the nuclear 5'-7-methylguanosine cap-binding complex, Ars2 promotes cotranscriptional processing coupled with nuclear export or degradation of several classes of RNAPII transcripts, allowing for gene expression programs that facilitate rapid and sustained proliferation of immortalized cells in culture. However, rapidly dividing cells in culture do not represent the physiological condition of the vast majority of cells in an adult mammal. To examine functions of Ars2 in a physiological setting, we generated inducible Ars2 knockout mice and found that deletion of Ars2 from adult mice resulted in defective hematopoiesis in bone marrow and thymus. Importantly, only some of this defect could be explained by the requirement of Ars2 for rapid proliferation, which we found to be cell-type specific in vivo. Rather, Ars2 was required for survival of developing thymocytes and for limiting differentiation of bone marrow resident long-term hematopoietic stem cells. As a result, Ars2 knockout led to rapid thymic involution and loss of the ability of mice to regenerate peripheral blood after myeloablation. These in vivo data demonstrate that Ars2 expression is important at several steps of hematopoiesis, likely because Ars2 acts on gene expression programs underlying essential cell fate decisions such as the decision to die,proliferate, or differentiate.

Indexed as

AnimalsApoptosisAsymmetric Cell DivisionBone MarrowCell Self RenewalClonal DeletionColony-Forming Units AssayDNA-Binding ProteinsGene Expression RegulationHematopoiesisHematopoietic Stem CellsMiceMice, Inbred StrainsMice, KnockoutNuclear ProteinsOrgan SpecificityDNA-Binding ProteinsNuclear ProteinsRecombinant ProteinsSrrt protein, mouseTranscription Factors

Identifiers

PMID29775646
PMCPMC6103522
OpenAlexW2804174839

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.